Recursion Pharmaceuticals
RXRX Small CapHealthcare · Biotechnology
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Recursion Pharmaceuticals en bref
Recursion Pharmaceuticals (RXRX) is currently trading at 2,60 € with a market capitalization of 1,4 Md €. The 52-week range spans from 2,40 € to 6,23 €; the current price is 58.2% below the yearly high. Year-over-year revenue growth stands at -56.1%.
💰 Dividende
Recursion Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
6 analystes évaluent Recursion Pharmaceuticals (RXRX) au consensus : None. L'objectif de cours moyen est de 6,29 €, soit un potentiel de +141.67% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 3,47 € à 8,67 €.
Recursion Pharmaceuticals : la thèse d'investissement en détail
Recursion Pharmaceuticals (RXRX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario baissier
Revenue is contracting at -56.1% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Short interest sits at 36.1% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 141.67% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Bilan solide avec faible endettement (D/E 7.06)
- –CA en contraction (-56.1% sur un an)
- –Positions vendeuses élevées (36.1%)
- –Free cash flow négatif
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (36.1%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Recursion Pharmaceuticals?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news